title: Inhibition of intestinal ischemia/repurfusion induced apoptosis and necrosis via down-regulation of the NF-kB, c-Jun and caspace-3 expression by epigallocatechin-3-gallate administration.
abstract: Intestinal ischemia/reperfusion (I/R) produces reactive oxygen species (ROS) activating signal transduction and apoptosis. The aim of this study was to evaluate the effect of (-)-epigallocatechin-3-gallate (EGCG) administration in inhibition of apoptosis by attenuating the expression of NF-kB, c-Jun and caspace-3 in intestinal I/R. Thirty male wistar rats were used. Group A sham operation, B I/R, C I/R-EGCG 50 mg/kg ip. Intestinal ischemia was induced for 60 min by clamping the superior mesenteric artery. Malondialdehyde (MDA), myeloperoxidase (MPO), light histology, Fragment End Labelling of DNA (TUNEL), immunocytochemistry for NF-kB, c-Jun and caspace-3 analysis in intestinal specimens were performed 120 min after reperfusion. Apoptosis as indicated by TUNEL and Caspace-3, NF-kB and c-Jun was widely expressed in I/R group but only slightly expressed in EGCG treated groups. MDA and MPO showed a marked increase in the I/R group and a significant decrease in the EGCG treated group. Light histology showed preservation of architecture in the EGCG treated group. In conclusion, EGCG pre-treatment is likely to inhibit intestinal I/R-induced apoptosis by down-regulating the expression of NF-kB, c-Jun and caspase-3.
authors.affiliation: Department of Transplant Surgery, Aristotle University, Thessaloniki, Greece.
authors.forename: Alexandros E
authors.initials: AE
authors.lastname: Giakoustidis
authors.forename: Dimitrios E
authors.initials: DE
authors.lastname: Giakoustidis
authors.forename: Kokona
authors.initials: K
authors.lastname: Koliakou
authors.forename: Eleni
authors.initials: E
authors.lastname: Kaldrymidou
authors.forename: Stavros
authors.initials: S
authors.lastname: Iliadis
authors.forename: Nickolaos
authors.initials: N
authors.lastname: Antoniadis
authors.forename: Nicholas
authors.initials: N
authors.lastname: Kontos
authors.forename: Vasilios
authors.initials: V
authors.lastname: Papanikolaou
authors.forename: Georgios
authors.initials: G
authors.lastname: Papageorgiou
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Atmatzidis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Takoudas
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3 / Q000378:metabolism; D002392:Catechin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015536:Down-Regulation / Q000187:drug effects*; D020287:In Situ Nick-End Labeling; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000098:blood supply* / Q000473:pathology; D007511:Ischemia / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000032:analysis; D008853:Microscopy; D016328:NF-kappa B / Q000378:metabolism; D009336:Necrosis / Q000188:drug therapy; D009195:Peroxidase / Q000378:metabolism; D016755:Proto-Oncogene Proteins c-jun / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000188:drug therapy*
chemical_list: D016328:NF-kappa B; D016755:Proto-Oncogene Proteins c-jun; D008315:Malondialdehyde; D002392:Catechin; C045651:epigallocatechin gallate; D009195:Peroxidase; D053148:Caspase 3